Synergy Pharmaceuticals Inc fka SGYPQ

[Opti Mist]

Synergy Pharmaceuticals 'Evaluating All Options': Does That Mean A Formal Strategic Review?
May 16, 2018 4:58 PM ET|3 comments | About: Synergy Pharmaceuticals, Inc. (SGYP), Includes: AGN

https://seekingalpha.com/article/4174830-synergy-pharmaceuticals-evaluating-options-mean-formal-strategic-review#alt1?source=email_rt_article_readmore

StrategyDoc

Summary
2018 Q 1 Sales of Trulance missed analyst expectations, while Allergan reported an 8% increase in Linzess for the previous quarter.

Frustrated Synergy shareholders holding some 26 million plus shares have come together to form an investor “insurrection.”.

On the most recent conference call, Synergy indicated the management team, along with their Board and unnamed advisors were evaluating all options, including potential partnerships and M&A.

Given the missteps by management since Trulance was approved by the FDA, there needs to be a formal strategic review that is more than merely considering "all options."

Opti